Immune reconstitution following high-dose chemotherapy and autologous stem cell transplantation with and without pembrolizumab maintenance therapy in patients with lymphoma

High-dose chemotherapy and autologous stem cell transplantation (ASCT) remain the standard of care for transplant-eligible patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) and diffuse large B-cell lymphoma (DLBCL) who respond to salvage chemotherapy.1 –3 The therapeutic benefit of ASCT has traditionally been attributed solely to cytoreduction from intensive chemotherapy; however, ASCT has important immunogenic effects which may also underlie some of its anti-tumor efficacy.

Source: Biology of Blood and Marrow Transplantation - October 17, 2021 Category: Hematology Authors: Reid W. Merryman, Robert Redd, Erin Jeter, Jeff L. Wong, Kristin McHugh, Carol Reynolds, Matthew Nazzaro, Aine Varden, Jennifer R. Brown, Jennifer L. Crombie, Matthew S. Davids, David C. Fisher, Eric Jacobsen, Caron A. Jacobson, Austin I. Kim, Ann S. LaCa Source Type: research